Hosted on MSN1d
GSK lowered to hold by Jefferies, valuation disconnect cited
Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
TipRanks on MSN2d
GSK downgraded to Hold from Buy at Jefferies
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
MedPage Today2d
Which High-Risk Patients Should Get the RSV Vaccine?
The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...
Daily3d
GSK RSV vaccine approved in Canada for adults aged 50-59 at increased risk
Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...
Health Canada approves Moderna’s mRNA RSV vaccine, company says
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...